CARA
Companies
NASDAQ
Cara Therapeutics Inc.
Health Care
$15.96
-$2.40 (-13.07%)
Price Chart
Overview
About CARA
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Market Cap
$34.1M
Volume
217.5K
Avg. Volume
208.0K
P/E Ratio
-6.103896
Dividend Yield
0.00%
Employees
76.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.17
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, CARA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$34.1M
Volume217.5K
P/E Ratio-6.10
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
March 12, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025